Загрузка...
Multicenter phase 1 trial of intraventricular immunochemotherapy in recurrent CNS lymphoma
Recurrent CNS lymphoma continues to be associated with poor outcomes in the rituximab era. Although IV rituximab mediates superior disease control of systemic non-Hodgkin lymphoma (NHL), it fails to completely eliminate the risk of meningeal recurrence, likely due to minimal CNS penetration. Given t...
Сохранить в:
| Главные авторы: | , , , , , , , , , , , , , , , |
|---|---|
| Формат: | Artigo |
| Язык: | Inglês |
| Опубликовано: |
American Society of Hematology
2013
|
| Предметы: | |
| Online-ссылка: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3563362/ https://ncbi.nlm.nih.gov/pubmed/23197589 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood-2012-07-440974 |
| Метки: |
Добавить метку
Нет меток, Требуется 1-ая метка записи!
|